SOLENO THERAPEUTICS, INC. 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 29th, 2023 • Soleno Therapeutics Inc • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledSeptember 29th, 2023 Company Industry JurisdictionSoleno Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,000,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 450,000 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
19,354,840 Shares of Common Stock SEELOS THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 21st, 2021 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 21st, 2021 Company Industry JurisdictionSeelos Therapeutics, Inc., a corporation organized and existing under the laws of the State of Nevada (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 19,354,840 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 2,903,226 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
30,303,030 Shares of Common Stock SOLENO THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • June 26th, 2020 • Soleno Therapeutics Inc • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledJune 26th, 2020 Company Industry JurisdictionSoleno Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 30,303,030 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 4,545,454 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).